Kelun — Biotech to debut Phase 3 TroFuse — 005 sac — TMT endometrial cancer data at ESMO 2026 Presidential Symposium
Kelun-Biotech flagged multiple readouts for its TROP2 ADC sacituzumab tirumotecan at the ESMO 2026 congress in Madrid. Data will be presented in late October, with several studies slated for oral sessions. Key disclosures include late-stage lung cancer results, positioned to inform first-line treatment choices or post-targeted therapy sequencing. A global pivotal endometrial cancer trial led by MSD is set for first presentation in a Presidential Symposium, raising visibility for the program. The slate also includes a Phase I update for SKB500, a B7-H3-targeted ADC, extending the company’s pipeline beyond TROP2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via (Ref. ID: CN70641) on October 13, 2026, and is solely responsible for the information contained therein. (C)
Kelun-Biotech flagged multiple readouts for its TROP2 ADC sacituzumab tirumotecan at the ESMO 2026 congress in Madrid. Data will be presented in late October, with several studies slated for oral sessions. Key disclosures include late-stage lung cancer results, positioned to inform first-line treatment choices or post-targeted therapy sequencing. A global pivotal endometrial cancer trial led by MSD is set for first presentation in a Presidential Symposium, raising visibility for the program.
The slate also includes a Phase I update for SKB500, a B7-H3-targeted ADC, extending the company’s pipeline beyond TROP2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. , Ltd.
published the original content used to generate this news brief via (Ref. ID: CN70641) on October 13, 2026, and is solely responsible for the information contained therein. (C)